Osteoarthritis — an untreatable disease? (original) (raw)

• Harris, E. D. Jr. The Bone and Joint decade: a catalyst for progress. Arthritis Rheum 44, 1969–1970 (2004).
  Article Google Scholar
• WHO Scientific group. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech. Rep. Ser. 919, 1–218 (2003). The tremendous challenge of the disease is summarized in this report of the epidemiology of musculoskeletal diseases.
• Merx, H. et al. International variation in hip replacement rates. Ann. Rheum. Dis. 62, 222–226 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• NIH Consensus Statement on Total Knee Replacement December 8–10, 2003. J. Bone Joint Surg. Am. 86, 1328–1335 (2004).
• Kean, W. F., Kean, R. & Buchanan, W. W. Osteoarthritis: symptoms, signs and source of pain. Inflammo-pharmacology 12, 3–31 (2004).
  Article CAS PubMed Google Scholar
• Badley, E. M. & Wang, P. P. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. J. Rheumatol. 25, 138–144 (1998).
  CAS PubMed Google Scholar
• Decision Resources, Inc. Osteoarthritis: Immune and Inflammatory Disorders Study (Decision Resources, Inc., Waltham, Massachusetts, 2004).
• Hannan, M. T., Felson, D. T. & Pincus, T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J. Rheumatol. 27, 1513–1517 (2000).
  CAS PubMed Google Scholar
• Flower, R. J. The development of COX2 inhibitors. Nature Rev. Drug. Discov. 2, 179–191 (2003). A comprehensive review of COX2 inhibitor development.
  Article CAS Google Scholar
• Topol, E. J. Failing the public health — Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351, 1707–1711 (2004).
  Article CAS PubMed Google Scholar
• Petit-Zeman, S. Characteristics of COX 2 inhibitors questioned. Nature Rev. Drug. Discov. 3, 726–727 (2004). This paper and reference10 provide evidence that the safety of COX2 inhibitors will be re-evaluated.
  Article CAS Google Scholar
• Felson, D. T. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol. Clin. N. Am. 42, 1–9 (2004).
  Article PubMed Google Scholar
• Spector, T. D. & MacGregor, A. J. Risk factors for osteoarthritis: genetics. Osteoarthr. Cartil. 12, S39–S44 (2004).
  Article PubMed Google Scholar
• Richette, P. & Bardin, T. Structure-modifying agents for osteoarthritis: an update. Joint Bone Spine 71, 18–23 (2004).
  Article PubMed Google Scholar
• Jordan, K. M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62, 1145–1155 (2003). Recent clinical recommendations issued by an osteoarthritis task force.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, W., Jones, A. & Doherty, M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 63, 901–907 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Neame, R., Zhang, W. & Doherty, M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Ann. Rheum. Dis. 63, 897–900 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, C., Straus, W. L., Balshaw, R., Barlas, S., Vogel, S. & Schnitzer, T. J. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 51, 746–754 (2004).
  Article CAS PubMed Google Scholar
• Vane, J. R., Bakhle, Y. S. & Botting, R. M. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. 38, 97–120 (1998).
  Article CAS Google Scholar
• Samad, T. A. et al. Interleukin-1β-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410, 471–475 (2001).
  Article CAS PubMed Google Scholar
• Watson, M. C., Brookes, S. T., Kirwan, J. R. & Faulkner, A. in The Cochrane Library, Issue 1 10.1002/14651858.CD000142 (Update Software Ltd, Oxford, 2003).
  Google Scholar
• Warner, T. D. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA 96, 7563–7568 (1999).
  Article CAS PubMed Google Scholar
• Bensen, W. G. et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc. 74, 1095–1105 (1999).
  Article CAS PubMed Google Scholar
• Day, R. et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch. Intern. Med. 160, 1781–1787 (2000).
  Article CAS PubMed Google Scholar
• McAlindon, T. E., LaValley, M. P., Gulin, J. P. & Felson, D. T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283, 1469–1475 (2000).
  Article CAS PubMed Google Scholar
• Zerkak, D. & Dougados, M. The use of glucosamine therapy in osteoarthritis. Curr. Pain Headache Rep. 8, 507–511 (2004).
  Article PubMed Google Scholar
• Chard, J & Dieppe, P. Glucosamine for osteoarthritis: magic, hype, or confusion? It's probably safe — but there's no good evidence that it works. BMJ 322, 1439–1440 (2001). This paper questions the validity of glucosamine as a treatment for OA.
  Article CAS PubMed PubMed Central Google Scholar
• Biggee, B. A. & McAlindon, T. Glucosamine for osteoarthritis: part I, review of the clinical evidence. Med. Health RI 87, 176–179 (2004).
  Google Scholar
• Lin, J., Zhang, W., Jones, A. & Doherty, M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta–analysis of randomised controlled trials. BMJ 329, 324 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Mason, L., Moore, R. A., Edwards, J. E., Derry, S. & McQuay, H. J. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet. Disord. 5, 28 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Ayral, X. Injections in the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. 15, 609–626 (2001).
  Article CAS PubMed Google Scholar
• Gossec, L. & Dougados, M. Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying. Ann. Rheum. Dis. 63, 478–482 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Creamer, P. Intra-articular corticosteroid treatment in osteoarthritis. Curr. Opin. Rheumatol. 11, 417–421 (1999).
  Article CAS PubMed Google Scholar
• Lohmander, L. S. et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann. Rheum. Dis. 55, 424–431 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Brandt, K. D., Smith, G. N. Jr & Simon, L. S. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum. 43, 1192–1203 (2000).
  Article CAS PubMed Google Scholar
• Lo, G. H., LaValley, M., McAlindon, T. & Felson, D. T. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA. 290, 3115–3221 (2003).
  Article CAS PubMed Google Scholar
• Berenbaum, F. Signaling transduction. Curr. Opin. Rheumatol. 16, 616–622 (2004).
  Article PubMed Google Scholar
• Haringman, J. J., Ludikhuize, J. & Tak, P. P. Chemokines in joint disease: the key to inflammation? Ann. Rheum. Dis. 63, 1186–1194 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Aigner, T. et al. Functional genomics of osteoarthritis. Pharmacogenomics 3, 635–650 (2002).
  Article CAS PubMed Google Scholar
• Fan, Z. et al. Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. Clin. Exp. Rheumatol. 22, 103–106 (2004).
  CAS PubMed Google Scholar
• Sandell, L. J. & Aigner, T. Articular cartilage and changes in osteoarthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 3, 107–113 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Matsumoto, T., Gargosky, S. E., Iwasaki, K. & Rosenfeld, R. G. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J. Clin. Endocrinol. Metab. 81, 150–155 (1996).
  CAS PubMed Google Scholar
• Lajeunesse, D. The role of bone in the treatment of osteoarthritis. Osteoarthr. Cartil. 12, S34–S38 (2004).
  Article PubMed Google Scholar
• Dumond, H. et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 48, 3118–3129 (2003). A recent perspective of leptin playing an important role in OA.
  Article CAS PubMed Google Scholar
• Figenschau, Y. et al. Human articular chondrocytes express functional leptin receptors. Biochem. Biophys. Res. Commun. 287, 190–197 (2001).
  Article CAS PubMed Google Scholar
• Lohmander, L. S., Atley, L. M., Pietka, T. A. & Eyre, D. R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 48, 3130–3139 (2003).
  Article CAS PubMed Google Scholar
• Rudolphi, K. et al. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr. Cartil. 11, 738–746 (2003).
  Article CAS PubMed Google Scholar
• Zhang, X., Mao, Z. & Yu, Ch. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J. Orthop. Res. 22, 742–750 (2004).
  Article CAS PubMed Google Scholar
• Fuchs, S. et al. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthr. Cartil. 12, 409–418 (2004).
  Article CAS PubMed Google Scholar
• Kevorkian, L. et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 50, 131–141 (2004).
  Article CAS PubMed Google Scholar
• Francois, M. et al. Peroxisome proliferator-activated receptor-γ down regulates chondrocyte matrix meatlloproteinase-1 via a novel composite element. J. Biol. Chem. 279, 28411–28418 (2004).
  Article CAS PubMed Google Scholar
• Bordji, K. et al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR)α and γ and retinoid Z receptor cartilage. J. Biol. Chem. 275, 12243–12250 (2000).
  Article CAS PubMed Google Scholar
• Martel-Pelletier, M., Pelletier, J. P. & Fahni, H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum. 33, 155–167 (2003).
  Article CAS PubMed Google Scholar
• Fahmi, H., Pelletier, J. P., Mineau, F. & Martel-Pelletier, J. 15d-PGJ2 is acting as “dual agent” on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthr. Cartil. 10, 845–848 (2002).
  Article CAS PubMed Google Scholar
• Aupperle, K. R. et al. NF-κB regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J. Immunol. 163, 427–433 (1999).
  CAS PubMed Google Scholar
• Aupperle, K. R. et al. Expression and regulation of inducible IκB kinase (IKK-i) in human fibroblast-like synoviocytes. Cell. Immunol. 214, 54–59 (2001).
  Article CAS PubMed Google Scholar
• Tegeder, I. et al. Specific inhibition of IκB kinase reduces hyperalgesia in inflammatory and neuropathic pain models. J. Neurosci. 24, 1673–1645 (2004).
  Article CAS Google Scholar
• Jobin, C. et al. Specific NF-κB blockade selectively inhibits tumour necrosis factor α-induced COX2 but not constitutive Cox-1 gene expression in HT29 cells. Immunology 95, 537–543 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Pelletier, J. -P. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthr. Cartil. 12 (Suppl. A), 63–68 (2003).
  Google Scholar
• Buckland-Wright, C. Subchondral bone changes in hand and knee osteoarthritis detected by radiography. Osteoarthr. Cartil. 12, (Suppl. A) 10–19 (2004).
  Article Google Scholar
• Felson, D. T. & Neogi, T. Osteoarthritis: is it a disease of cartilage or bone? Arthritis Rheum. 50, 341–344 (2004). A recent paper discussing the contribution of both cartilage and bone to the progression of the disease.
  Article PubMed Google Scholar
• Grynpas, M. D., Alpert, B., Katz, I., Lieberman, I. & Pritzker, K. P. Subchondral bone in osteoarthritis. Calcif. Tissue Int. 49, 20–26 (1991).
  Article CAS PubMed Google Scholar
• Hayami, T. et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 50, 1193–1206 (2004).
  Article CAS PubMed Google Scholar
• Doschak, M. R., Wohl, G. R., Hanley, D. A., Bray, R. C. & Zernicke, R. F. Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J. Orthop. Res. 22, 942–948 (2004).
  Article CAS PubMed Google Scholar
• Myers, S. L., Brandt, K. D., Burr, D. B., O'Connor, B. L. & Albrecht, M. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J. Rheumatol. 26, 2645–2653 (1999).
  CAS PubMed Google Scholar
• Bingham, C. et al. Clinically significant placebo improvement occurs by 6 months and is maintained through 24 months in a study of knee OA pain and function. Osteoarthr. Cartil. 12, S132 Abs. P323 (2004).
  Google Scholar
• Menkes, C. J. & Lane, N. E. Are osteophytes good or bad? Osteoarthr. Cartil. 12, S53–S54 (2004).
  Article PubMed Google Scholar
• Uchino, M. et al. Growth factor expression in the osteophytes of the human femoral head in osteoarthritis. Clin. Orthop. 377, 119–125 (2000).
  Article Google Scholar
• Brandt, K. D. Osteophytes in osteoarthritis. Clinical aspects. Osteoarthr. Cartil. 7, 334–335 (1999).
  Article CAS PubMed Google Scholar
• Van Osch, G. J., Van der Kraan, P. M., Van Valburg, A. A. & Van den Berg, W. B. The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee. Rheumatol. Int. 16, 115–119 (1996).
  Article CAS PubMed Google Scholar
• Lanyon, P., O'Reilly, S., Jones, A. & Doherty, M. Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space. Ann. Rheum. Dis. 57, 595–601 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ghosh, P. Vascular mechanisms in osteoarthritis. Best Practice Res. Clin. Rheumatol. 15, 693–710 (2001).
  Article CAS Google Scholar
• Simkin, P. A. in Osteoarthritic Joint Pain (Novartis Foundation Symposium) 179–190 (Wiley, Chichester, 2004).
  Google Scholar
• Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305–317 (2002).
  Article CAS PubMed Google Scholar
• Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197–207 (2000).
  Article CAS PubMed Google Scholar
• Ahima, R. S. & Flier, J. S. Leptin. Annu. Rev. Physiol. 62, 413–437 (2000).
  Article CAS PubMed Google Scholar
• Dean, G., Hoyland, J. A., Denton, J., Donn, R. P. & Freemont, A. J. Mast cells in the synovium and synovial fluid in osteoarthritis. Br. J. Rheumatol. 32, 671–675 (1993).
  Article CAS PubMed Google Scholar
• Lindblad, S. & Hedfors, E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis Rheumatol. 30, 1081–1088 (1987).
  Article CAS Google Scholar
• Halverson, P. B. & Derfus, B. A. Calcium crystal-induced inflammation. Curr Opin. Rheumatol. 13, 221–224 (2001).
  Article CAS PubMed Google Scholar
• Kato, T., Xiang, Y., Nakamura, H. & Nishioka, K. Neoantigens in osteoarthritic cartilage. Curr. Opin. Rheumatol. 16, 604–608 (2004).
  Article CAS PubMed Google Scholar
• Abramson, S. B. Inflammation in osteoarthritis. J. Rheumatol. Suppl. 70, 70–76 (2004).
  CAS PubMed Google Scholar
• Poole, A. R. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum. Dis. Clin. North Am. 29, 803–818 (2003). This paper provides a classic review on biomarkers in OA.
  Article PubMed Google Scholar
• Mapp, P. I. Innervation of the synovium. Ann. Rheum. Dis. 54, 398–403 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Opree, A. & Kress, M. Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20, 6289–6293 (2000).
  Article CAS PubMed Google Scholar
• Safieh-Garabedian, B., Poole, S., Allchorne, A., Winter, J. & Woolf, C. J. Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol. 115, 1265–1275 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Woolf, C. J., Allchorne, A., Safieh-Garabedian, B. & Poole, S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α. Br. J. Pharmacol. 121, 417–424 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, X., Tanner, K. & Levine, J. D. Mechanical sensitization of cutaneous C-fiber nociceptors by prostaglandin E2 in the rat. Neurosci. Lett. 267, 105–108 (1999).
  Article CAS PubMed Google Scholar
• Manning, D. C., Raja, S. N., Meyer, R. A. & Campbell, J. N. Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin. Pharmacol. Ther. 50, 721–729 (1991).
  Article CAS PubMed Google Scholar
• Mizumura, K. Natural history of nociceptor sensitization — the search for peripheral mechanism of hyperalgesia. Pain Rev. 5, 59–82 (1998).
  Article CAS Google Scholar
• Flechtenmacher, J. et al. Bradykinin-receptor-inhibition — a therapeutic option in osteoarthritis? Osteoarthr. Cartil. 12, S137 Abs. P332 (2004).
  Google Scholar
• Saito, T. & Koshino, T. Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin. Orthop. 376, 172–182 (2000).
  Article Google Scholar
• Vilensky, J. A. & Cook, J. A. Neurogenic acceleration of osteoarthritis. Curr. Opin. Rheumatol. 10, 251–255 (1998).
  Article CAS PubMed Google Scholar
• Hurley, M. V., Scott, D. L., Rees, J. & Newham, D. J. Sensorimotor changes and functional performance in patients with knee osteoarthritis. Ann. Rheum. Dis. 56, 641–648 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Baker, K. & McAlindon, T. Exercise for knee osteoarthritis. Curr. Opin. Rheumatol. 12, 456–463 (2000).
  Article CAS PubMed Google Scholar
• Slemenda, C. et al. Quadriceps weakness and osteoarthritis of the knee. Ann. Int. Med. 127, 97–104 (1997).
  Article CAS PubMed Google Scholar
• Becker, R., Berth, A., Nehring, M. & Awiszus, F. Neuromuscular quadriceps dysfunction prior to osteoarthritis of the knee. J. Orthop. Res. 22, 768–773 (2004).
  Article PubMed Google Scholar
• O'Connor, B. L. & Vilensky, J. A. Peripheral and central nervous system mechanisms of joint protection. Am. J. Orthop. 32, 330–336 (2003).
  PubMed Google Scholar
• Sharma, L., Dunlop, D. D., Cahue, S., Song, J. & Hayes, K. W. Quadriceps strength and osteoarthritis progression in malaligned and lax knees. Ann. Intern. Med. 138, 613–619 (2003).
  Article PubMed Google Scholar
• Creamer, P., Hunt, M. & Dieppe, P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. J. Rheumatol. 23, 1031–1036 (1996).
  CAS PubMed Google Scholar
• Schaible, H. G., Ebersberger, A., Von Banchet, G. S. Mechanisms of pain in arthritis. Ann. NY Acad. Sci. 966, 343–354 (2002).
  Article CAS PubMed Google Scholar
• Kidd, B. L. & Urban, L. A. Mechanisms of inflammatory pain. Br. J. Anaesth. 87, 3–11 (2001).
  Article CAS PubMed Google Scholar
• US Department of Health and Human Services, Food and Drug Administration. Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [online], <http://www.who.int/intellectualproperty/documents/en/FDAproposals.pdf> (2004).
• Butcher, E. C., Berg, E. L. & Kunkel, E. J. Systems biology in drug discovery. Nature Biotechnology 22, 1253–1259 (2004).
  Article CAS PubMed Google Scholar
• Bonnet, C. S. & Walsh, D. A. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44, 7–16 (2005). An interesting recent review illustrating the relevance of angiogenic processes to the pathophysiology of OA.
  Article CAS Google Scholar
• Walsh, D. A. Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes. Curr. Opin. Rheumatol. 16, 609–615 (2004).
  Article PubMed Google Scholar
• Balint, G. & Szebenyi, B. Hereditary disorders mimicking and/or causing premature osteoarthritis. Baillieres Best. Pract. Res. Clin. Rheumatol. 14, 219–250 (2000).
  Article CAS PubMed Google Scholar
• Dequeker, J., Boonen, N., Aerssens, J. & Westhovens, R. Inverse relationship osteoarthritis — osteoporosis: what is the evidence? What are the consequences? Br. J. Rheumatol. 35, 813–820 (1996).
  Article CAS PubMed Google Scholar
• Lark, M. W. & Blake, S. M. Development of novel therapeutics to treat joint diseases — what can be learned from other diseases? Curr. Opin. Pharmacol. 4, 273–275 (2004).
  Article CAS Google Scholar
• Aspden, R. M., Scheven, B. A. A. & Hutchison, J. D. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet 357, 1118–1120 (2001). One of the first publications suggesting a direct relationship between OA and metabolic disorders.
  Article CAS PubMed Google Scholar
• Toda, Y. et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after weight control program. J. Rheumatol. 25, 2181–2186 (1998).
  CAS PubMed Google Scholar
• Gimble, J. M. & Nuttall, M. E. Bone and fat. Endocrine 23, 183–188 (2004)
  Article CAS PubMed Google Scholar
• Loeser, R. F. Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle? Arthritis Rheum. 48, 3009–3012 (2003)
  Article CAS PubMed Google Scholar
• Yagami, K. et al. A human chondrogenic cell line retains multi-potency that differentiates into osteoblasts and adipocytes. Bone 34, 648–655 (2004).
  Article CAS PubMed Google Scholar
• Henroitin, Y., Sanchez, C. & Reginster, J. Y. The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin. Ther. Patents 12, 29–43 (2002).
  Article Google Scholar
• Skiles, J. W., Gonella, N. C. & Jeng, A. Y. The design, structure and clinical update of small metalloproteinase inhibitors. Curr. Med. Chem. 11, 2911–2977 (2004).
  Article CAS PubMed Google Scholar
• Schnitzer, T. J. et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 364, 665–674 (2004).
  Article CAS PubMed Google Scholar
• Brune, K. Safety of anti-inflammatory treatment — new ways of thinking. Rheumatology (Oxford). 43 S16–S20 (2004).
  Article CAS Google Scholar
• Ding, C & Cicuttini, F. Licofelone (Merckle). IDrugs 6, 802–808 (2003).
  CAS PubMed Google Scholar
• Wallace, J. L. & Del Soldato, P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 17, 11–20 (2003).
  Article CAS PubMed Google Scholar
• Whittle, B. J. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr. Opin. Pharmacol. 4, 538–545 (2004).
  Article CAS PubMed Google Scholar
• Schnitzer, T. J., Kivitz, A. J., Lipetz, S., Sanders, N. & Hee, A. A Phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritis of the knee. Eur. League Against Rheumatism 2004 Conference Abs OP0016 [online], <http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2004SCIE-abstract&TEMPLATE=&keyf=0094&showHide=show&client=> (2004)
• Garnero, P. et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 46, 2613–2624 (2002).
  Article CAS PubMed Google Scholar
• Cerejo, R. et al. The association between cartilage activity measured in serum and progression of knee osteoarthritis in patients with and without evidence of generalized disease. Arthritis Rheum. 46, S144 (2002).
  Article Google Scholar
• Sharif, M. et al. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum. 50, 2479–2488 (2004).
  Article CAS PubMed Google Scholar
• Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discovery 3, 711–715 (2004).
  Article CAS Google Scholar